Larotrectinib

Drug Profile

Larotrectinib

Alternative Names: LOXO-101

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II CNS cancer
  • Preclinical Acute lymphoblastic leukaemia

Most Recent Events

  • 24 Feb 2017 Loxo Oncology collaborates with NCI Formulary to co-develop larotrectinib in Cancer
  • 16 Jan 2017 Loxo Oncology initiates an expanded-access programme for Cancer in USA (PO, Capsule and PO, Liquid) (NCT03025360)
  • 23 Dec 2016 Loxo Oncology announces intention to submit NDA and MAA for Solid tumours in 2017 and 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top